Acción BVNRY BAVARIAN NORDIC A/S
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Bavarian Nordic A/S OTC Markets

Acciones

BVNRY

US0717711099

Mercado cerrado - OTC Markets
Otros sitios de cotización
 21:30:54 10/06/2024 		Varia. Cinco días. Varia. 1 de enero.
8,52 USD -1,73 % Gráfico intradía de Bavarian Nordic A/S -4,49 % -2,57 %
31/05 Bavarian Nordic solicita una licencia suplementaria en EE.UU. para la vacuna contra la viruela y la viruela del mono MT
30/05 Bavarian Nordic obtiene 6,5 millones de dólares de financiación para el desarrollo de una vacuna contra el Mpox en niños MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
Bavarian Nordic A/S : Transactions in Connection with Share Buy Back Program and Termination of Share Buy Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
Bavarian Nordic’s Medical Chief to Step Down by May-end
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.
Bavarian Nordic A/S : Interim Results (Q1) as of 31 March 2024
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BAVA
  4. Acción BVNRY
  5. Noticias Bavarian Nordic A/S
  6. Otros idiomas